PT2007770E - Compostos imidazo - Google Patents
Compostos imidazo Download PDFInfo
- Publication number
- PT2007770E PT2007770E PT07728052T PT07728052T PT2007770E PT 2007770 E PT2007770 E PT 2007770E PT 07728052 T PT07728052 T PT 07728052T PT 07728052 T PT07728052 T PT 07728052T PT 2007770 E PT2007770 E PT 2007770E
- Authority
- PT
- Portugal
- Prior art keywords
- alkyl
- aryl
- compound
- alkoxycarbonyl
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 229910052739 hydrogen Chemical group 0.000 claims 4
- 239000001257 hydrogen Chemical group 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- -1 benzo [b] thiophenyl Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- ZWWCURLKEXEFQT-UHFFFAOYSA-N dinitrogen pentaoxide Chemical compound [O-][N+](=O)O[N+]([O-])=O ZWWCURLKEXEFQT-UHFFFAOYSA-N 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 1
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005103 alkyl silyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000000369 oxido group Chemical group [*]=O 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (10)
- ΡΕ2007770 1 REIVINDICAÇÕES 1. Um composto da fórmula geral(l) na qual R é deutério, halogéneo ou hidrogénio; R1 é aril-alquilo C0-C4 ou heterociclil-alquilo C0-C4, grupos esses que podem ser substituídos por 1-4 alcoxi C1-C8, (alcoxi Ci-Cs) carbonilo, alquilo Ci-Cs, (alquil C0-C8)carbonilo, (alquil Ci-Cs)sulfonilo, arilo facultativamente substituído, aril-(alcoxi C0-C4)carbonilo, ciano, halogéneo, heterociclilo não substituído ou substituído, hidroxi, nitro, óxido, oxo, tri-(alquil C1-C4) sililo, tri-fluorometoxi ou trifluorometilo; pelo que heterociclilo representa um sistema em anel monocíclico, de 4-8 membros, saturado, parcialmente saturado ou insaturado, um sistema em anel bicíclico, de 7-12 membros, parcialmente saturado ou insaturado, e também um sistema em anel tricíclico, de 9-12 membros, parcialmente saturado ou insaturado, o qual compreende um átomo de N, 0 ou S em pelo menos um dos anéis, sendo possível para um átomo de N, 0 ou S adicional estar presente num anel, e pelo que arilo representa um hidrocarboneto aromático mono, bi ou tricíclico concordando com a regra de Huckel que geralmente compreende 6-14 átomos de carbono, 2 ΡΕ2007770 R2 é a) deutério, halogéneo, hidroxi, ciano ou hidrogénio; ou b) alcenilo C2-Cs, alcinilo C2-C8, alcoxi Ci-C8, (alcoxi C1-C4) carbonil-alquilo C1-C4, alquilo Ci-C8, (alquil C0-C4) carbonilo, aril-alquilo C0-C4, carboxi-alquilo C1-C4, cicloalquilo C3-C8 ou heterociclil-alquilo C0-C4, grupos esses que podem ser substituídos por 1-4 alcoxi Ci-Cg, (alcoxi Ci-C8) carbonilo, alquilo Ci-Cs, (alquil Co-C8) carbonilo, (alquil Ci-Cs)-sulfonilo, arilo não substituído ou substituído, aril-(alcoxi C0-C4)carbonilo, ciano, halogéneo, heterociclilo não substituído ou substituído, hidroxi, nitro, óxido, oxo, tri-(alquil C1-C4)-sililo, trifluorometoxi ou trifluorometilo; Q é oxigénio ou enxofre; m é um número 0, 1 ou 2; n é um número 0, 1 ou 2; onde m e n não são simultaneamente 0; pelo que os substituintes nos grupos arilo ou grupos fenilo ou naftilo preferidos são: alcoxi Ci-C8, (alcoxi Ci-C8)-carbonilo, alquilo Ci-C8, (alquil C0-C8) carbonilo, (alquil Ci-Cs) sulfonilo, arilo facultativamente substituído, aril-(alcoxi C0-C4) carbonilo, ciano, halogéneo, heterociclilo facultativamente substituído, hidroxi, nitro, tri-(Ci-C4 alquil)sililo, trifluorometoxi ou trifluorometilo, os substituintes nos grupos heterociclilo são: alcoxi Ci-Cs, (alcoxi Ci-Cs) carbonilo, alquilo Ci-Cs, (alquil Cq-Cs)- 3 ΡΕ2007770 carbonilo, (alquil Ci-Ce)sulfonilo, arilo facultativamente substituído, aril-(alcoxi C0-C4)carbonilo, ciano, halogé-neo, heterociclilo facultativamente substituído, hidroxi, nitro, óxido, oxo, tri-(alquil C1-C4)sililo, trifluorometo-xi ou trifluorometilo, e um seu sal, preferivelmente um sal farmaceuticamente aceitável.
- 2. Um composto de acordo com a Reivindicação 1, o qual corresponde à fórmula geralonde os significados dos substituintes R, R1, R2, Q, m e n são conforme indicado para os compostos da fórmula (I) de acordo com a Reivindicação 1, e * designa um átomo de carbono assimétrico e em que o composto mostra uma actividade inibidora de aldosterona-sintase e/ou ΙΙ-β-hidroxilase pelo menos 10 vezes mais alta, mas preferivelmente 20 vezes mais alta, ou mais preferivelmente 40 vezes mais alta, do que o composto da fórmula (Ia) com a configuração oposta à volta do átomo de carbono assimétrico assinalado .
- 3. Um composto de acordo com a Reivindicação 1 ou 2, onde R é deutério ou hidrogénio. Um composto de acordo com qualquer uma das 4 .
- 4 ΡΕ2007770 Reivindicações 1 a 3, onde R1 é fenilo facultativamente mono, di ou trissubstituido ou facultativamente mono, di ou trissubstituido benzofuranilo, benzo[b]tiofenilo, benzimi-dazolilo, benzo[d]isotiazolilo, benzo[d]isoxazolilo, benzo-[b]tiofenilo, imidazolilo, indazolilo, oxazolilo, piridilo, pirrolilo, tiazolilo ou tiofenilo.
- 5. Um composto de acordo com qualquer uma das Reivindicações 1 a 4, onde R2 é alcoxi Ci-Cs, hidroxi, alquilo Ci-C8, aril-alquilo C0-C4, deutério, halogéneo, ciano ou hidrogénio.
- 6. 0 uso de um composto da fórmula geral (I) ou (Ia) ou um seu sal farmaceuticamente aceitável de acordo com qualquer uma das Reivindicações 1 a 5 para o fabrico de um medicamento.
- 7. 0 uso de um composto da fórmula geral (I) ou (Ia) ou um seu sal farmaceuticamente aceitável de acordo com qualquer uma das Reivindicações 1 a 5 para o fabrico de um medicamento humano para a prevenção, para o retardamento da progressão ou para o tratamento de estados patológicos que são causados ou parcialmente causados por hiperal-dosteronismo.
- 8. 0 uso de um composto da fórmula geral (I) ou (Ia) ou um seu sal farmaceuticamente aceitável de acordo com qualquer uma das Reivindicações 1 a 5 para o fabrico de um medicamento humano para a prevenção, para o retardamento 5 ΡΕ2007770 da progressão ou para o tratamento de estados patológicos que são causados ou parcialmente causados pela libertação excessiva de cortisol.
- 9. Um produto farmacêutico compreendendo um composto da fórmula geral (I) ou (Ia) ou um seu sal farmaceuticamente aceitável de acordo com qualquer uma das Reivindicações 1 a 5, e excipientes convencionais.
- 10. Uma combinação farmacêutica na forma de um produto ou de um kit composto de componentes individuais consistindo a) de um composto da fórmula geral (I) ou (Ia) ou um seu sal farmaceuticamente aceitável de acordo com qualquer uma das Reivindicações 1 a 5, e b) de pelo menos uma forma farmacêutica cujo ingrediente activo tem um efeito de abaixamento da pressão sanguínea, inotrópico, antidiabético, de redução da obesidade ou de abaixamento de lípido. Lisboa, 15 de Outubro de 2011
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH6202006 | 2006-04-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2007770E true PT2007770E (pt) | 2010-10-21 |
Family
ID=38462029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT07728052T PT2007770E (pt) | 2006-04-12 | 2007-04-12 | Compostos imidazo |
| PT07728054T PT2007771E (pt) | 2006-04-12 | 2007-04-12 | Compostos imidazo |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT07728054T PT2007771E (pt) | 2006-04-12 | 2007-04-12 | Compostos imidazo |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20090192149A1 (pt) |
| EP (2) | EP2007771B1 (pt) |
| JP (2) | JP2009534319A (pt) |
| CN (2) | CN101421279B (pt) |
| AR (1) | AR060590A1 (pt) |
| AT (2) | ATE463498T1 (pt) |
| BR (2) | BRPI0711540A2 (pt) |
| CA (2) | CA2649213A1 (pt) |
| DE (2) | DE602007005788D1 (pt) |
| ES (2) | ES2352358T3 (pt) |
| IL (2) | IL194584A0 (pt) |
| PL (2) | PL2007770T3 (pt) |
| PT (2) | PT2007770E (pt) |
| TW (1) | TW200808813A (pt) |
| WO (2) | WO2007116099A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200616623A (en) * | 2004-05-28 | 2006-06-01 | Speedel Experimenta Ag | Organic compounds |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| UY32660A (es) | 2009-05-28 | 2010-12-31 | Novartis Ag | Derivados aminobutricos sustituidos como inhibidores de neprilisina |
| ME01923B (me) | 2009-05-28 | 2015-05-20 | Novartis Ag | Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| LT2956464T (lt) | 2013-02-14 | 2018-07-10 | Novartis Ag | Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai |
| AP2016009019A0 (en) | 2013-07-25 | 2016-02-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| JP6501775B2 (ja) | 2013-07-25 | 2019-04-17 | ノバルティス アーゲー | 心不全治療用の環状ポリペプチド |
| RS57570B1 (sr) * | 2014-07-24 | 2018-10-31 | Boehringer Ingelheim Int | Inhibitori aldosteron sintaze |
| PE20171328A1 (es) | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de acidos grasos y apelina sintetica con mayor vida media |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| EP3887388A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| US11958818B2 (en) | 2019-05-01 | 2024-04-16 | Boehringer Ingelheim International Gmbh | (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2023114170A1 (en) | 2021-12-14 | 2023-06-22 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors for treating chronic kidney disease |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0670064B2 (ja) * | 1986-12-08 | 1994-09-07 | 三井石油化学工業株式会社 | 二環性イミダゾ−ル誘導体 |
| WO1997000257A1 (en) * | 1995-06-14 | 1997-01-03 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| AR032316A1 (es) * | 2000-04-12 | 2003-11-05 | Novartis Ag | Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica |
| AU2003253387A1 (en) * | 2002-08-07 | 2004-02-25 | Novartis Ag | Organic compounds as agents for the treatment of aldosterone mediated conditions |
| TW200616623A (en) * | 2004-05-28 | 2006-06-01 | Speedel Experimenta Ag | Organic compounds |
| CN1956987A (zh) | 2004-05-28 | 2007-05-02 | 斯皮德尔实验股份公司 | 杂环化合物及其作为醛固酮合酶抑制剂的应用 |
| EP1748986B1 (en) * | 2004-05-28 | 2010-12-01 | Novartis AG | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| WO2006005726A2 (en) * | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
-
2007
- 2007-04-10 TW TW096112449A patent/TW200808813A/zh unknown
- 2007-04-11 AR ARP070101536A patent/AR060590A1/es unknown
- 2007-04-12 AT AT07728054T patent/ATE463498T1/de active
- 2007-04-12 CA CA002649213A patent/CA2649213A1/en not_active Abandoned
- 2007-04-12 CN CN2007800132920A patent/CN101421279B/zh not_active Expired - Fee Related
- 2007-04-12 US US12/226,212 patent/US20090192149A1/en not_active Abandoned
- 2007-04-12 EP EP07728054A patent/EP2007771B1/en active Active
- 2007-04-12 JP JP2009504757A patent/JP2009534319A/ja active Pending
- 2007-04-12 WO PCT/EP2007/053585 patent/WO2007116099A1/en not_active Ceased
- 2007-04-12 PL PL07728052T patent/PL2007770T3/pl unknown
- 2007-04-12 PT PT07728052T patent/PT2007770E/pt unknown
- 2007-04-12 WO PCT/EP2007/053587 patent/WO2007116101A1/en not_active Ceased
- 2007-04-12 DE DE602007005788T patent/DE602007005788D1/de not_active Expired - Fee Related
- 2007-04-12 PT PT07728054T patent/PT2007771E/pt unknown
- 2007-04-12 CA CA002649217A patent/CA2649217A1/en not_active Abandoned
- 2007-04-12 EP EP07728052A patent/EP2007770B1/en not_active Not-in-force
- 2007-04-12 BR BRPI0711540-7A patent/BRPI0711540A2/pt not_active IP Right Cessation
- 2007-04-12 AT AT07728052T patent/ATE480545T1/de active
- 2007-04-12 JP JP2009504755A patent/JP5260496B2/ja not_active Expired - Fee Related
- 2007-04-12 ES ES07728052T patent/ES2352358T3/es active Active
- 2007-04-12 US US12/226,214 patent/US7879847B2/en not_active Expired - Fee Related
- 2007-04-12 BR BRPI0710614-9A patent/BRPI0710614A2/pt not_active IP Right Cessation
- 2007-04-12 PL PL07728054T patent/PL2007771T3/pl unknown
- 2007-04-12 DE DE602007009074T patent/DE602007009074D1/de active Active
- 2007-04-12 ES ES07728054T patent/ES2342689T3/es active Active
- 2007-04-12 CN CNA2007800129595A patent/CN101421277A/zh active Pending
-
2008
- 2008-10-06 IL IL194584A patent/IL194584A0/en unknown
- 2008-10-06 IL IL194583A patent/IL194583A0/en unknown
-
2010
- 2010-12-22 US US12/975,949 patent/US8138176B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2007770E (pt) | Compostos imidazo | |
| CA2641473A1 (en) | Condensed imidazole derivatives as aldosterone synthase inhibitors | |
| ES2754207T3 (es) | Inhibidores de la ARN polimerasa I y usos de los mismos | |
| Yang et al. | Celastrus orbiculatus extract triggers apoptosis and autophagy via PI3K/Akt/mTOR inhibition in human colorectal cancer cells | |
| JP2009520038A5 (pt) | ||
| Wang et al. | Piperlongumine induces apoptosis and autophagy in leukemic cells through targeting the PI3K/Akt/mTOR and p38 signaling pathways | |
| WO2014182643A2 (en) | Methods for treating hcv infection | |
| BR112019020464A2 (pt) | compostos derivados de heteroarila bicíclica, composição farmacêutica compreendendo os ditos compostos, adesivo transdérmico compreendendo a dita composição e uso terapêutico dos compostos e composição | |
| Xu et al. | ECRG4 inhibits growth and invasiveness of squamous cell carcinoma of the head and neck in vitro and in vivo | |
| EP3328368B1 (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| BRPI0615968B1 (pt) | Uso de um composto, composto e composição farmacêutica | |
| AU2022202183B2 (en) | Cancer treatment | |
| Chen et al. | Tetrandrine triggers apoptosis and cell cycle arrest in human renal cell carcinoma cells | |
| WO2010133742A1 (es) | Uso de derivados de quinazolinas en enfermedades neurodegenerativas | |
| Zeng et al. | Selective stabilization of multiple promoter G-quadruplex DNA by using 2-phenyl-1H-imidazole-based tanshinone IIA derivatives and their potential suppressing function in the metastatic breast cancer | |
| BRPI0517740A (pt) | compostos n-sulfonilaminobenzil-2fenóxi acetamida substituìda | |
| BaLLazhI et al. | Potential antiproliferative effect of isoxazolo-and thiazolo coumarin derivatives on breast cancer mediated bone and lung metastases | |
| Caputi et al. | Evidence of a PPARγ-mediated mechanism in the ability of Withania somnifera to attenuate tolerance to the antinociceptive effects of morphine | |
| EP3129361A1 (en) | Treatment of neurodegenerative diseases with asparagine endopeptidase (aep) inhibitors and compositions related thereto | |
| CA3084846A1 (en) | Heteroaryl amide compounds, preparation method therefor, pharmaceutical compositions thereof, and applications thereof | |
| Shah et al. | Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma | |
| BR112018012934B1 (pt) | Reguladores cftr e métodos de uso dos mesmos | |
| US9877949B2 (en) | Anticancer treatment methods involving analogs and derivatives of 3-(2-substituted-ethyl) indole compounds | |
| Jiang et al. | Novel targets and small molecular interventions for liver cancer | |
| Shentu et al. | Anti-proliferative activity of fenretinide in human hepatoma cells in vitro and in vivo |